by Jennifer R. Eads, MD; Thorvardur R. Halfdanarson, MD; and Jonathan R. Strosberg, MD
Somatostatin analogues (SSAs) are a therapeutic mainstay for the treatment of neuroendocrine tumors (NETs) and carcinoid syndrome, but, when progre......READ MORE
Genetic testing has a role in the care of patients with neuroendocrine tumors (NETs), especially in younger patients with NETs and in cases of NETs......READ MORE
Image-based monitoring for patients with advanced neuroendocrine tumors (NETs) can be individualized based on the NET site and tumor characteristic......READ MORE
by Jennifer R. Eads, MD; Thorvardur R. Halfdanarson, MD; and Jonathan R. Strosberg, MD
The treatment of neuroendocrine tumors (NETs) and carcinoid syndrome is individualized for each patient based on a number of factors. Successful ap......READ MORE
Small-bowel neuroendocrine tumors (NETs) will eventually progress during ongoing somatostatin analogue (SSA) therapy. Treatment options for progres......READ MORE
Patients with neuroendocrine tumors (NETs) and carcinoid syndrome who are being treated with somatostatin analogue (SSA) therapy may still experien......READ MORE